Compare BKD & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKD | WGS |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2005 | 2020 |
| Metric | BKD | WGS |
|---|---|---|
| Price | $9.89 | $66.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $19.08 | ★ $93.50 |
| AVG Volume (30 Days) | ★ 4.7M | 739.2K |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $4,531,426,000.00 | $427,539,000.00 |
| Revenue This Year | N/A | $12.70 |
| Revenue Next Year | $2.55 | $24.31 |
| P/E Ratio | $143.43 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $8.02 | $32.21 |
| 52 Week High | $17.09 | $170.87 |
| Indicator | BKD | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 21.87 | 36.97 |
| Support Level | $9.74 | $56.36 |
| Resistance Level | $14.36 | $73.21 |
| Average True Range (ATR) | 0.36 | 4.58 |
| MACD | -0.03 | -0.82 |
| Stochastic Oscillator | 6.93 | 15.85 |
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.